BIORQ

0.00010.00%
JK

James Knight

Head of Business Development

Mr. James Knight, also known as Jim, MBA, served as Chief Business Officer at SynAct Pharma AB since February 2021 until Septemebr 05, 2025 and serves as its Member of Advisory Board from September 05, 2025. He serves as Head of Business Development at Biora Therapeutics Inc. since February 2024. He served as Senior Vice President of Corporate Development & Head of Corporate Development at Lineage Cell Therapeutics, Inc. since October 2016. He has experience in creating portfolio value at publicly-traded companies including, Questcor Pharmaceuticals, Inc. and Elan Pharmaceuticals. He served as Vice President of Strategic Marketing at Questcor Pharmaceuticals, Inc., where he was responsible for leading the expansion of Acthar Gel from two promoted indications in two specialty audiences to nine promoted indications in five specialty areas including rheumatology. Questcor's success in expanding Acthar use led to its acquisition by Mallinckrodt. He was the Vice President of Portfolio Strategy at Questcor from 2010 to 2014. Before joining Questcor in November 2010, he served as the US Director for Healthcare Consulting at Datamonitor. He was at Elan Pharmaceuticals from 2001 to 2008, where he led a global strategic marketing team, working closely with collaborators at Biogen Inc. on the successful development and commercialization of Tysabri, a monoclonal antibody. He served as Vice President of Global Strategic Marketing at Elan Pharmaceuticals and held various positions in market research and brand management at Dura Pharmaceuticals. He started his career at Biogen (now Biogen Idec) as an Associate Scientist in Pharmacology. He was an Independent Consultant providing strategic marketing consulting services to early-stage biopharmaceutical companies. Mr. Knight has a Bachelor of Science in Biology from the University of Massachusetts, Amherst and an Master of Business Administration in High Technology from Northeastern University.

Positions